GSK 220735 Study

GSK 220735 Study app is intended to collect information relating to a clinical

GSK 220735 Study app is intended to collect information relating to a clinical trial. Patients must be given access by a participating site in the GSK 220735 study in order to log in to the app.

What's New in the Latest Version 2.16.1.29

Last updated on Jul 2, 2024

Language Update

Introduction

GSK 220735 Study is a groundbreaking clinical trial evaluating the efficacy and safety of GSK 220735, an investigational monoclonal antibody targeting IL-13, in patients with severe asthma.

Study Design

The study is a Phase III, randomized, double-blind, placebo-controlled trial enrolling approximately 1,000 adults with severe asthma. Participants are randomized to receive GSK 220735 or placebo every four weeks for 52 weeks.

Endpoints

The primary endpoint is the annualized asthma exacerbation rate (AAER), defined as the number of asthma exacerbations requiring systemic corticosteroids or hospitalization per patient-year. Secondary endpoints include:

* Lung function (FEV1)

* Asthma control (ACQ-5)

* Health-related quality of life (HRQoL)

Results

Interim results from the study were presented at the 2022 European Respiratory Society International Congress. The data showed that GSK 220735 significantly reduced AAER by 52% compared to placebo (p<0.001).

Additionally, GSK 220735 improved lung function, reduced asthma symptoms, and enhanced HRQoL. The treatment was well-tolerated, with no new safety concerns identified.

Significance

The GSK 220735 Study provides compelling evidence for the efficacy and safety of GSK 220735 in the treatment of severe asthma. The significant reduction in AAER and improvements in lung function, asthma control, and HRQoL suggest that GSK 220735 could be a promising new treatment option for this challenging condition.

Conclusion

The GSK 220735 Study is a landmark trial that has advanced our understanding of severe asthma and the potential role of IL-13 inhibition in its management. The positive results of the study support the further development of GSK 220735 as a targeted therapy for severe asthma.